These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 16997053

  • 1. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M, Franke S, Wolf G, Brandstädt A, Ott U, Gerth J, Hunsicker LG, Stein G, Collaborative Study Group.
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [Abstract] [Full Text] [Related]

  • 2. [Is the serum concentration of pentosidine a predictor of cardiovascular events in patients with type 2 diabetes and kidney disease?].
    Busch M, Franke S, Stein G, Wolf G, Collaborative Study Group.
    Dtsch Med Wochenschr; 2007 Sep; 132(36):1810-4. PubMed ID: 17726651
    [Abstract] [Full Text] [Related]

  • 3. Serum carboxymethyllysine predicts mortality in hemodialysis patients.
    Wagner Z, Molnár M, Molnár GA, Tamaskó M, Laczy B, Wagner L, Csiky B, Heidland A, Nagy J, Wittmann I.
    Am J Kidney Dis; 2006 Feb; 47(2):294-300. PubMed ID: 16431258
    [Abstract] [Full Text] [Related]

  • 4. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M, Franke S, Wolf G, Rohde RD, Stein G, Collaborative Study Group.
    Nephron Clin Pract; 2008 Feb; 108(4):c291-7. PubMed ID: 18434751
    [Abstract] [Full Text] [Related]

  • 5. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.
    Nakamura S, Tachikawa T, Tobita K, Aoyama I, Takayama F, Enomoto A, Niwa T.
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S68-71. PubMed ID: 12612956
    [Abstract] [Full Text] [Related]

  • 6. Clinical and prognostic value of advanced glycation end-products in chronic heart failure.
    Hartog JW, Voors AA, Schalkwijk CG, Scheijen J, Smilde TD, Damman K, Bakker SJ, Smit AJ, van Veldhuisen DJ.
    Eur Heart J; 2007 Dec; 28(23):2879-85. PubMed ID: 17986469
    [Abstract] [Full Text] [Related]

  • 7. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
    Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H.
    Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
    [Abstract] [Full Text] [Related]

  • 8. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M, Fleck C, Wolf G, Stein G.
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study.
    Kilhovd BK, Juutilainen A, Lehto S, Rönnemaa T, Torjesen PA, Birkeland KI, Berg TJ, Hanssen KF, Laakso M.
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):815-20. PubMed ID: 15692098
    [Abstract] [Full Text] [Related]

  • 11. Plasma levels of advanced glycation end products in children with renal disease.
    Sebeková K, Podracká L, Blazícek P, Syrová D, Heidland A, Schinzel R.
    Pediatr Nephrol; 2001 Dec; 16(12):1105-12. PubMed ID: 11793110
    [Abstract] [Full Text] [Related]

  • 12. Effects of gender, Helicobacter pylori and hepatitis B virus serology status on cardiovascular and renal complications in Chinese type 2 diabetic patients with overt nephropathy.
    Lo MK, Lee KF, Chan NN, Leung WY, Ko GT, Chan WB, So WY, Ng MC, Ho CS, Tam JS, Lam CW, Tong PC, Chan JC.
    Diabetes Obes Metab; 2004 May; 6(3):223-30. PubMed ID: 15056131
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy.
    Endo M, Yanagisawa K, Tsuchida K, Okamoto T, Matsushita T, Higuchi M, Matsuda A, Takeuchi M, Makita Z, Koike T.
    Horm Metab Res; 2001 May; 33(5):317-22. PubMed ID: 11440280
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A novel advanced glycation index and its association with diabetes and microangiopathy.
    Sampathkumar R, Balasubramanyam M, Rema M, Premanand C, Mohan V.
    Metabolism; 2005 Aug; 54(8):1002-7. PubMed ID: 16092048
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Severity of diabetic microvascular complications is associated with a low soluble RAGE level.
    Grossin N, Wautier MP, Meas T, Guillausseau PJ, Massin P, Wautier JL.
    Diabetes Metab; 2008 Sep; 34(4 Pt 1):392-5. PubMed ID: 18701333
    [Abstract] [Full Text] [Related]

  • 19. Concomitant macro and microvascular complications in diabetic nephropathy.
    Alwakeel JS, Al-Suwaida A, Isnani AC, Al-Harbi A, Alam A.
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):402-9. PubMed ID: 19414942
    [Abstract] [Full Text] [Related]

  • 20. Serum cystatin C in diabetic patients. Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy.
    Ogawa Y, Goto T, Tamasawa N, Matsui J, Tando Y, Sugimoto K, Tomotsune K, Kimura M, Yasujima M, Suda T.
    Diabetes Res Clin Pract; 2008 Feb; 79(2):357-61. PubMed ID: 17980929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.